A novel start-loss mutation of the SLC29A3 gene in a consanguineous family with H syndrome: clinical characteristics, in silico analysis and literature review.
SLC29A3 gene
H syndrome
Hyperpigmentation
Novel mutation
Whole-exome sequencing, Iran
Journal
BMC medical genomics
ISSN: 1755-8794
Titre abrégé: BMC Med Genomics
Pays: England
ID NLM: 101319628
Informations de publication
Date de publication:
04 Jul 2024
04 Jul 2024
Historique:
received:
04
03
2024
accepted:
24
06
2024
medline:
5
7
2024
pubmed:
5
7
2024
entrez:
4
7
2024
Statut:
epublish
Résumé
The SLC29A3 gene, which encodes a nucleoside transporter protein, is primarily located in intracellular membranes. The mutations in this gene can give rise to various clinical manifestations, including H syndrome, dysosteosclerosis, Faisalabad histiocytosis, and pigmented hypertrichosis with insulin-dependent diabetes. The aim of this study is to present two Iranian patients with H syndrome and to describe a novel start-loss mutation in SLC29A3 gene. In this study, we employed whole-exome sequencing (WES) as a method to identify genetic variations that contribute to the development of H syndrome in a 16-year-old girl and her 8-year-old brother. These siblings were part of an Iranian family with consanguineous parents. To confirmed the pathogenicity of the identified variant, we utilized in-silico tools and cross-referenced various databases to confirm its novelty. Additionally, we conducted a co-segregation study and verified the presence of the variant in the parents of the affected patients through Sanger sequencing. In our study, we identified a novel start-loss mutation (c.2T > A, p.Met1Lys) in the SLC29A3 gene, which was found in both of two patients. Co-segregation analysis using Sanger sequencing confirmed that this variant was inherited from the parents. To evaluate the potential pathogenicity and novelty of this mutation, we consulted various databases. Additionally, we employed bioinformatics tools to predict the three-dimensional structure of the mutant SLC29A3 protein. These analyses were conducted with the aim of providing valuable insights into the functional implications of the identified mutation on the structure and function of the SLC29A3 protein. Our study contributes to the expanding body of evidence supporting the association between mutations in the SLC29A3 gene and H syndrome. The molecular analysis of diseases related to SLC29A3 is crucial in understanding the range of variability and raising awareness of H syndrome, with the ultimate goal of facilitating early diagnosis and appropriate treatment. The discovery of this novel biallelic variant in the probands further underscores the significance of utilizing genetic testing approaches, such as WES, as dependable diagnostic tools for individuals with this particular condition.
Sections du résumé
BACKGROUND
BACKGROUND
The SLC29A3 gene, which encodes a nucleoside transporter protein, is primarily located in intracellular membranes. The mutations in this gene can give rise to various clinical manifestations, including H syndrome, dysosteosclerosis, Faisalabad histiocytosis, and pigmented hypertrichosis with insulin-dependent diabetes. The aim of this study is to present two Iranian patients with H syndrome and to describe a novel start-loss mutation in SLC29A3 gene.
METHODS
METHODS
In this study, we employed whole-exome sequencing (WES) as a method to identify genetic variations that contribute to the development of H syndrome in a 16-year-old girl and her 8-year-old brother. These siblings were part of an Iranian family with consanguineous parents. To confirmed the pathogenicity of the identified variant, we utilized in-silico tools and cross-referenced various databases to confirm its novelty. Additionally, we conducted a co-segregation study and verified the presence of the variant in the parents of the affected patients through Sanger sequencing.
RESULTS
RESULTS
In our study, we identified a novel start-loss mutation (c.2T > A, p.Met1Lys) in the SLC29A3 gene, which was found in both of two patients. Co-segregation analysis using Sanger sequencing confirmed that this variant was inherited from the parents. To evaluate the potential pathogenicity and novelty of this mutation, we consulted various databases. Additionally, we employed bioinformatics tools to predict the three-dimensional structure of the mutant SLC29A3 protein. These analyses were conducted with the aim of providing valuable insights into the functional implications of the identified mutation on the structure and function of the SLC29A3 protein.
CONCLUSION
CONCLUSIONS
Our study contributes to the expanding body of evidence supporting the association between mutations in the SLC29A3 gene and H syndrome. The molecular analysis of diseases related to SLC29A3 is crucial in understanding the range of variability and raising awareness of H syndrome, with the ultimate goal of facilitating early diagnosis and appropriate treatment. The discovery of this novel biallelic variant in the probands further underscores the significance of utilizing genetic testing approaches, such as WES, as dependable diagnostic tools for individuals with this particular condition.
Identifiants
pubmed: 38965556
doi: 10.1186/s12920-024-01949-w
pii: 10.1186/s12920-024-01949-w
doi:
Substances chimiques
SLC29A3 protein, human
0
Nucleoside Transport Proteins
0
Types de publication
Journal Article
Case Reports
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
178Subventions
Organisme : Golestan University of Medical Sciences, Iran, Islamic Republic Of
ID : 112526
Informations de copyright
© 2024. The Author(s).
Références
Molho-Pessach V, Lerer I, Abeliovich D, Agha Z, Libdeh AA, Broshtilova V, et al. The H syndrome is caused by mutations in the nucleoside transporter hENT3. Am J Hum Genet. 2008;83(4):529–34.
doi: 10.1016/j.ajhg.2008.09.013
pubmed: 18940313
pmcid: 2561939
Fraitag S, Emile JF. Cutaneous histiocytoses in children. Histopathology. 2022;80(1):196–215.
doi: 10.1111/his.14569
pubmed: 34958507
Li R, Mak WW-S, Li J, Zheng C, Shiu PH-T, Seto S-W, et al. Structure-activity relationship studies of 4-((4-(2-fluorophenyl) piperazin-1-yl) methyl)-6-imino-N-(naphthalen-2-yl)-1, 3, 5-triazin-2-amine (FPMINT) Analogues as inhibitors of human equilibrative Nucleoside transporters. Front Pharmacol. 2022;13:837555.
doi: 10.3389/fphar.2022.837555
pubmed: 35264969
pmcid: 8899516
Kang N, Jun AH, Bhutia YD, Kannan N, Unadkat JD, Govindarajan R. Human equilibrative nucleoside transporter-3 (hENT3) spectrum disorder mutations impair nucleoside transport, protein localization, and stability. J Biol Chem. 2010;285(36):28343–52.
doi: 10.1074/jbc.M110.109199
pubmed: 20595384
pmcid: 2934698
Govindarajan R, Leung GP, Zhou M, Tse C-M, Wang J, Unadkat JD. Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol. 2009;296(4):G910–22.
doi: 10.1152/ajpgi.90672.2008
pubmed: 19164483
pmcid: 2670673
Al-Haggar M, Salem N, Wahba Y, Ahmad N, Jonard L, Abdel‐Hady D, et al. Novel homozygous SLC29A3 mutations among two unrelated Egyptian families with spectral features of H‐syndrome. Pediatr Diabetes. 2015;16(4):305–16.
doi: 10.1111/pedi.12160
pubmed: 24894595
Molho-Pessach V, Varma M, Godbole K, Kamath N, Zlotogorski A. H syndrome–four new patients from India. Indian J Dermatol Venereol Leprol. 2014;80(6):579.
doi: 10.4103/0378-6323.144229
pubmed: 25382534
Shankar SG, Rangarajan S, Priyadarshini A, Swaminathan A, Sundaram M. Homozygosity for a novel large deletion in SLC29A3 in a patient with H syndrome. Pediatr Dermatol. 2020;37(2):333–6.
doi: 10.1111/pde.14075
pubmed: 31867772
Jacquot R, Jouret M, Valentin MG, Richard M, Jamilloux Y, Rousset F et al. H syndrome treated with Tocilizumab: two case reports and literature review. Front Immunol. 2023;14.
Kopanos C, Tsiolkas V, Kouris A, Chapple CE, Aguilera MA, Meyer R, et al. VarSome: the human genomic variant search engine. Bioinformatics. 2019;35(11):1978–80.
doi: 10.1093/bioinformatics/bty897
pubmed: 30376034
Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2019;47(D1):D886–94.
doi: 10.1093/nar/gky1016
pubmed: 30371827
Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods. 2014;11(4):361–2.
doi: 10.1038/nmeth.2890
pubmed: 24681721
Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013;76(1):1–52.
Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31(13):3812–4.
doi: 10.1093/nar/gkg509
pubmed: 12824425
pmcid: 168916
Thomas PD, Ebert D, Muruganujan A, Mushayahama T, Albou LP, Mi H. PANTHER: making genome-scale phylogenetics accessible to all. Protein Sci. 2022;31(1):8–22.
doi: 10.1002/pro.4218
pubmed: 34717010
Shihab HA, Gough J, Cooper DN, Stenson PD, Barker GL, Edwards KJ, et al. Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. Hum Mutat. 2013;34(1):57–65.
doi: 10.1002/humu.22225
pubmed: 23033316
Cheng J, Randall A, Baldi P. Prediction of protein stability changes for single-site mutations using support vector machines. Proteins. 2006;62(4):1125–32.
doi: 10.1002/prot.20810
pubmed: 16372356
Capriotti E, Fariselli P, Casadio R. I-Mutant2. 0: predicting stability changes upon mutation from the protein sequence or structure. Nucleic Acids Res. 2005;33(suppl2):W306–10.
doi: 10.1093/nar/gki375
pubmed: 15980478
pmcid: 1160136
Sievers F, Higgins DG. Clustal Omega, accurate alignment of very large numbers of sequences. Methods Mol Biol. 2014;1079:105–16.
doi: 10.1007/978-1-62703-646-7_6
pubmed: 24170397
Hamsho S, Alaswad M, Sleiay M, Alhusseini A. Hyperglycemia with hypogonadism and growth hormone deficiency in a 17-year-old male with H syndrome: the first case report from Syria. BMC Endocr Disord. 2023;23(1):274.
doi: 10.1186/s12902-023-01525-w
pubmed: 38093297
pmcid: 10720192
Molho-Pessach V, Agha Z, Aamar S, Glaser B, Doviner V, Hiller N, et al. The H syndrome: a genodermatosis characterized by indurated, hyperpigmented, and hypertrichotic skin with systemic manifestations. J Am Acad Dermatol. 2008;59(1):79–85.
doi: 10.1016/j.jaad.2008.03.021
pubmed: 18410979
Bolze A, Abhyankar A, Grant AV, Patel B, Yadav R, Byun M, et al. A mild form of SLC29A3 disorder: a frameshift deletion leads to the paradoxical translation of an otherwise noncoding mRNA splice variant. PLoS ONE. 2012;7(1):e29708.
doi: 10.1371/journal.pone.0029708
pubmed: 22238637
pmcid: 3251605
Bloom JL, Lin C, Imundo L, Guthery S, Stepenaskie S, Galambos C, et al. H syndrome: 5 new cases from the United States with novel features and responses to therapy. Pediatr Rheumatol Online J. 2017;15(1):76.
doi: 10.1186/s12969-017-0204-y
pubmed: 29041934
pmcid: 5645937
Chouk H, Ben Rejeb M, Boussofara L, Elmabrouk H, Ghariani N, Sriha B, et al. Phenotypic intrafamilial variability including H syndrome and Rosai–Dorfman disease associated with the same c. 1088G > A mutation in the SLC29A3 gene. Hum Genomics. 2021;15:1–10.
doi: 10.1186/s40246-021-00362-z
Amalnath D, Lingala R, Subrahmanyam D. H syndrome presenting with sinus of Valsalva Aneurysm and possible founder mutation (p.Arg134cys) in Indian patients. Indian J Dermatology. 2023;68(3):344–6.
Doviner V, Maly A, Ne’eman Z, Qawasmi R, Aamar S, Sultan M, et al. H syndrome: recently defined genodermatosis with distinct histologic features. A morphological, histochemical, immunohistochemical, and ultrastructural study of 10 cases. Am J Dermatopathol. 2010;32(2):118–28.
doi: 10.1097/DAD.0b013e3181b28572
pubmed: 20010285
Morgan NV, Morris MR, Cangul H, Gleeson D, Straatman-Iwanowska A, Davies N, et al. Mutations in SLC29A3, encoding an equilibrative nucleoside transporter ENT3, cause a familial histiocytosis syndrome (Faisalabad histiocytosis) and familial Rosai-Dorfman disease. PLoS Genet. 2010;6(2):e1000833.
doi: 10.1371/journal.pgen.1000833
pubmed: 20140240
pmcid: 2816679
Cliffe ST, Kramer JM, Hussain K, Robben JH, de Jong EK, de Brouwer AP, et al. SLC29A3 gene is mutated in pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome and interacts with the insulin signaling pathway. Hum Mol Genet. 2009;18(12):2257–65.
doi: 10.1093/hmg/ddp161
pubmed: 19336477
Campeau PM, Lu JT, Sule G, Jiang MM, Bae Y, Madan S, et al. Whole-exome sequencing identifies mutations in the nucleoside transporter gene SLC29A3 in dysosteosclerosis, a form of osteopetrosis. Hum Mol Genet. 2012;21(22):4904–9.
doi: 10.1093/hmg/dds326
pubmed: 22875837
pmcid: 3607481
Molho-Pessach V, Suarez J, Perrin C, Chiaverini C, Doviner V, Tristan-Clavijo E, et al. The H syndrome: two novel mutations affecting the same amino acid residue of hENT3. J Dermatol Sci. 2010;57(1):59–61.
doi: 10.1016/j.jdermsci.2009.09.011
pubmed: 19889517
Spiegel R, Cliffe ST, Buckley MF, Crow YJ, Urquhart J, Horovitz Y, et al. Expanding the clinical spectrum of SLC29A3 gene defects. Eur J Med Genet. 2010;53(5):309–13.
doi: 10.1016/j.ejmg.2010.06.012
pubmed: 20619369
Noavar S, Behroozi S, Tatarcheh T, Parvini F, Foroutan M, Fahimi H. A novel homozygous frame-shift mutation in the SLC29A3 gene: a new case report and review of literature. BMC Med Genet. 2019;20(1):1–7.
doi: 10.1186/s12881-019-0879-7
Alkaya DU, Akpinar E, Bilguvar K, Tuysuz B. Resolution of sclerotic lesions of dysosteosclerosis due to biallelic SLC29A3 variant in a Turkish girl. Am J Med Genet A. 2021;185(7):2271–7.
doi: 10.1002/ajmg.a.62198
Besci O, Patel KA, Yıldız G, Tüfekçi O, Acinikli KY, Erbaş İM, et al. Atypical comorbidities in a child considered to have type 1 diabetes led to the diagnosis of SLC29A3 spectrum disorder. Hormones (Athens Greece). 2022;21(3):501–6.
doi: 10.1007/s42000-022-00352-3
pubmed: 35284993
Demir D, Aktaş Karabay E, Sözeri B, Gürsoy F, Akgün Doğan Ö, Topaktaş E, et al. H syndrome with a novel homozygous SLC29A3 mutation in two sisters. Pediatr Dermatol. 2020;37(6):1135–8.
doi: 10.1111/pde.14322
pubmed: 32776596
Turan S, Mumm S, Alavanda C, Kaygusuz BS, Gurpinar Tosun B, Arman A, et al. Dysosteosclerosis: clinical and radiological evolution reflecting genetic heterogeneity. JBMR plus. 2022;6(8):e10663.
doi: 10.1002/jbm4.10663
pubmed: 35991533
pmcid: 9382861
Cardis MA, Srinivasalu H, Greenberg J, Norton SA. Hyperpigmented and hypertrichotic sclerotic plaques in a child. Pediatr Dermatol. 2020;37(5):937–8.
doi: 10.1111/pde.14258
pubmed: 32981165
Vural S, Ertop P, Durmaz CD, Şanlı H, Okçu Heper A, Kundakçı N, et al. Skin-dominant phenotype in a patient with H syndrome: identification of a novel mutation in the SLC29A3 gene. Cytogenet Genome Res. 2017;151(4):186–90.
doi: 10.1159/000475908
pubmed: 28554179
Huizing M, Gahl WA. Inherited disorders of lysosomal membrane transporters. Biochim Biophys Acta Biomembr. 2020;1862(12):183336.
doi: 10.1016/j.bbamem.2020.183336
pubmed: 32389669
pmcid: 7508925